Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | AOC2 | O75106 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17828102 | 0.86 | USP2 (0.58) | USP2ALDH1A1ANPEPSMN1; SMN2KEAP1 | |
| SCHEMBL9944693 | 0.84 | PIK3CD (0.37) | ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL3841536 | 0.84 | — | — | |
| SCHEMBL15354727 | 0.80 | USP2 (0.52) | USP2ALDH1A1ANPEPSMN1; SMN2LMNA | |
| SCHEMBL10192059 | 0.80 | USP2 (0.52) | USP2ALDH1A1ANPEPSMN1; SMN2LMNA | |
| SCHEMBL3917497 | 0.79 | KMT2A (0.42) | ALDH1A1ANPEPLMNAKDM4EMEN1 | |
| SCHEMBL21778028 | 0.79 | KMT2A (0.42) | ALDH1A1ANPEPLMNAKDM4EMEN1 | |
| SCHEMBL13931 | 0.79 | KMT2A (0.42) | ALDH1A1ANPEPLMNAKDM4EMEN1 | |
| SCHEMBL19976505 | 0.79 | USP2 (0.47) | USP2ALDH1A1ANPEPSMN1; SMN2KEAP1 | |
| SCHEMBL9547004 | 0.79 | USP2 (0.47) | USP2ALDH1A1ANPEPSMN1; SMN2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938249-B2 | Anti-amyloid compounds containing benzofurazan | TREVENTIS CORPORATION (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170174641-A1 | ANTI-AMYLOID COMPOUNDS CONTAINING BENZOFURAZAN | TREVENTIS CORPORATION (US) | 2017-06-22 | — | — | US | disclosed |
| US-5639770-A | SUPEROXIDE INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-06-17 | — | — | US | disclosed |
| EP-0600092-A1 | THIAZOLE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174641-A1 | ANTI-AMYLOID COMPOUNDS CONTAINING BENZOFURAZAN | PRNP, PSEN1, APP | USP2 4467/4885ALDH1A1 1441/4885ANPEP 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.